Genzyme Corp.'s not-yet-completed \$1 billion acquisition of Ilex Oncology Inc. appeared to pay off yesterday when an advisory committee to the Food and Drug Administration recommended the agency approve Ilex's experimental cancer treatment for children with certain types of leukemia.